Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 10

1.

Targeting Melanoma with Cancer-Killing Viruses.

Zhang T, Suryawanshi YR, Woyczesczyk HM, Essani K.

Open Virol J. 2017 Mar 31;11:28-47. doi: 10.2174/1874357901711010028. eCollection 2017.

2.

Oncolytic herpes viruses, chemotherapeutics, and other cancer drugs.

Braidwood L, Graham SV, Graham A, Conner J.

Oncolytic Virother. 2013 Dec 4;2:57-74. doi: 10.2147/OV.S52601. eCollection 2013. Review.

3.

Oncolytic viruses in the treatment of bladder cancer.

Potts KG, Hitt MM, Moore RB.

Adv Urol. 2012;2012:404581. doi: 10.1155/2012/404581. Epub 2012 Jul 29.

4.

Biological effects of a de novo designed myxoma virus peptide analogue: evaluation of cytotoxicity on tumor cells.

Istivan TS, Pirogova E, Gan E, Almansour NM, Coloe PJ, Cosic I.

PLoS One. 2011;6(9):e24809. doi: 10.1371/journal.pone.0024809. Epub 2011 Sep 19.

5.

Targeting HSV-1 virions for specific binding to epidermal growth factor receptor-vIII-bearing tumor cells.

Grandi P, Fernandez J, Szentirmai O, Carter R, Gianni D, Sena-Esteves M, Breakefield XO.

Cancer Gene Ther. 2010 Sep;17(9):655-63. doi: 10.1038/cgt.2010.22. Epub 2010 May 28.

6.

Effects of herpes simplex virus amplicon transduction on murine dendritic cells.

Chiu YG, Bowers WJ, Lim ST, Ryan DA, Federoff HJ.

Hum Gene Ther. 2009 May;20(5):442-52. doi: 10.1089/hum.2008.160.

7.

Recombinant Newcastle disease virus as a vaccine vector for cancer therapy.

Vigil A, Martinez O, Chua MA, GarcĂ­a-Sastre A.

Mol Ther. 2008 Nov;16(11):1883-90. doi: 10.1038/mt.2008.181. Epub 2008 Aug 19.

8.

Herpes simplex virus NV1020 as a novel and promising therapy for hepatic malignancy.

Kelly KJ, Wong J, Fong Y.

Expert Opin Investig Drugs. 2008 Jul;17(7):1105-13. doi: 10.1517/13543784.17.7.1105 . Review.

9.

Utility of a herpes oncolytic virus for the detection of neural invasion by cancer.

Gil Z, Kelly KJ, Brader P, Shah JP, Fong Y, Wong RJ.

Neoplasia. 2008 Apr;10(4):347-53.

10.

Use of an oncolytic virus secreting GM-CSF as combined oncolytic and immunotherapy for treatment of colorectal and hepatic adenocarcinomas.

Malhotra S, Kim T, Zager J, Bennett J, Ebright M, D'Angelica M, Fong Y.

Surgery. 2007 Apr;141(4):520-9. Epub 2007 Feb 14.

Supplemental Content

Support Center